Mayne Pharma Group Ltd. · ASX:MYX

Mayne Pharma — Merger or Acquisition (August 2016)

10 slides from Mayne Pharma's merger presentation, Aug 18, 2016

  1. Slide 1: Acquisition of GSK Foam Assets

    For personal use only Acquisition of GSK Foam Assets Mayne Pharma Group Limited 18 August 2016 1

  2. Slide 2: Overview of the Foam Assets transaction

    For personal use only 1 Overview of the Foam Assets transaction

  3. Slide 3: Transaction overview

    Transaction overview For personal use only Mayne Pharma has acquired a portfolio of foam dermatology products and related assets (“Foam Assets”) from GlaxoSmithKline (“GSK”) for US$50.1 million  Fabior® and Sorilux® are patent-protected foam products currently marketed in the US and are considered

  4. Slide 4: Compelling strategic rationale underpins the acquisition of Foam Assets

    Compelling strategic rationale underpins the acquisition of Foam Assets For personal use only ● Strengthens Mayne Pharma’s presence in US dermatology market ● Fabior® uniquely positioned and complementary acne product to Doryx® Complementary to ● Sorilux® provides entry point into attractive psorias

  5. Slide 5: Market overview – Topical acne market and psoriasis market

    Market overview – Fabior® and Sorilux® Topical acne market (Fabior®) TRx weekly count - Topical single active retinoid market3 For personal use only ● Acne is the most prevalent skin disease in the US 120,000 affecting 50 million people with most seeking 100,000 initial treatment during puberty and

  6. Slide 6: Product overviews: Fabior and Sorilux

    Product overviews: Fabior® and Sorilux® For personal use only Fabior® Description ● Tazarotene Foam, 0.1% Regulatory status ● FDA approved 2012, launched September 2013 Clinical studies ● Two phase 3 studies were conducted in ~1,500 patients with moderate to severe acne Indication ● Treatment of acn

  7. Slide 7: Commercial execution plan

    Commercial execution plan For personal use only ● Following sales team training, finalisation of marketing materials, key opinion leader briefings and pricing and reimbursement, Mayne Pharma expects to re-launch Fabior® and Sorilux® in early calendar 2017 ● GSK will continue to distribute the produc

  8. Slide 8: Fabior complements the existing Doryx acne franchise

    Fabior® complements the existing Doryx® acne franchise First line acne treatment2 For personal use only ● Dermatologists often prescribe more than one Fabior Doryx Oral Topical product to treat acne and many use a combination of a topical product with an oral antibiotic Acne ● Topical retinoids are

  9. Slide 9: Doryx franchise

    For personal use only 2 Doryx® franchise

  10. Slide 10: Doryx franchise update

    Doryx® franchise update Mayne Pharma branded and generic weekly doxycycline 200mg and 50mg branded and generic For personal use only hyclate delayed-release tablets prescriptions (TRx)1 (50mg and 200mg)  Total market weekly TRx ~4,400 7,000  In June, retained 80%+ of doxycycline delayed- Launch of

Mayne Pharma Group — Merger or Acquisition (August 2016) on 6ix